Effectiveness of Thrombin–Collagen and Autologous Platelet-Rich Plasma in Total Hip Arthroplasty Hemostasis: A Prospective, Randomized, Controlled Trial


Bovine derived thrombin–collagen combined with autologous platelet-rich plasma (PRP) has shown promise as a topical, surgical hemostatic agent. The purpose of this study was to determine the effect of thrombin–collagen–PRP on perioperative blood loss in total hip arthroplasty (THA). A prospective, single-blinded, randomized, controlled study comparing thrombin–collagen–PRP use to standard treatment was performed. All patients undergoing elective primary THA for osteoarthritis by a single physician at a single institution were included. Thirty-nine patients were enrolled. There was no significant difference in estimated total blood loss or blood transfusions received. There was no significant difference in operative blood loss, drain output, daily postoperative hematocrit, change in hematocrit, or length of stay. There is insufficient evidence to support the routine use of a topical thrombin–collagen–autologous PRP hemostatic agent in primary total hip arthroplasty. (Journal of Surgical Orthopaedic Advances 27(2):136–141, 2018)
Key words: collagen, hemostasis, platelet-rich plasma, PRP, thrombin, total hip arthroplasty

SKU: JSOA-2018-27-2-S10 Categories: , Tags: , , , , ,

Eric N. Bowman, MD, MPH; Michael P. McCabe, MD; and Kevin B. Cleveland, MD